

26 ¹⁰ *Department of Microbiology, Tumor and Cell Biology, Division of Clinical Microbiology,*

27 *Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden*

28 ¹¹ *Molecular and Integrative Biosciences Research Programme, University of Helsinki,*

29 *Helsinki, Finland*

30 ¹² *Infection Management Prevention Service, Queensland Children's Hospital, Brisbane,*

31 *Queensland, Australia.*

32

33 #Current Address: Wellcome-Wolfson Institute for Experimental Medicine, School of

34 Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United

35 Kingdom.

36 ^Current address: INRAE, Univ Montpellier, LBE, 102 Avenue des Etangs, Narbonne 11100,

37 France.

38

39 **Running title:** High risk neonatal meningitis *E. coli* clones

40 **Word count:** Text (3493 words), Abstract (249 words).

41

42 ***Corresponding authors:**

43 Professor Mark Schembri, Institute for Molecular Bioscience, The University of Queensland,

44 Brisbane, Queensland 4072, Australia. E-mail: m.schembri@uq.edu.au.

45 Dr Adam Irwin, Centre for Clinical Research, University of Queensland, Brisbane,

46 Queensland, Australia. Email: a.irwin@uq.edu.au.

47

49 **Abstract**

50 Neonatal meningitis is a devastating disease associated with high mortality and neurological
51 sequelae. *Escherichia coli* is the second most common cause of neonatal meningitis (herein
52 NMEC) and the most common cause of meningitis in preterm neonates. Here we investigated
53 the genomic relatedness of a collection of NMEC strains spanning 1974-2020 and isolated
54 from seven different geographic regions. We show NMEC are comprised of strains from
55 diverse sequence types (STs), with ST95 (34.5%) and ST1193 (15.5%) the most common. No
56 single virulence factor was conserved in all strains; however, genes encoding fimbrial
57 adhesins, iron acquisition systems, the K1 capsule, and O antigen types O18, O75 and O2
58 were most prevalent. Antibiotic resistance genes occurred infrequently. We also monitored
59 the infection dynamics in three patients that suffered relapsed infection caused by the original
60 infecting strain despite appropriate antibiotic treatment based on antibiogram profile and
61 resistance genotype. These patients exhibited severe gut dysbiosis. In one patient, the
62 causative NMEC isolate was also detected in the fecal flora at the time of the second
63 infection episode and after treatment. Thus, although antibiotics are the standard of care for
64 NMEC treatment, our data suggests that failure to eliminate the causative NMEC that resides
65 intestinally can lead to the existence of a refractory reservoir that may seed recrudescence
66 infection.

67

68 **Key words:** *E. coli*, neonatal meningitis, genomics, relapse infection, gut dysbiosis

69 **Introduction**

70 Neonatal meningitis (NM) is a devastating disease with a mortality rate of 10-15% and severe
71 neurological sequelae including hearing loss, reduced motor skills and impaired development
72 in 30-50% of cases [1-3]. The incidence of disease is highest in low-income countries and
73 occurs at a rate of 0.1-6.1/1000 live births [3]. *Escherichia coli* is the second most common
74 cause of NM (herein NMEC), after group B *Streptococcus* (GBS) [4, 5], and the most
75 common cause of meningitis in preterm neonates [5, 6]. Together, these two pathogens cause
76 ~60% of all cases, with on average one case of NMEC for every two cases of GBS [7, 8]. In
77 several countries, NM incidence caused by GBS has declined due to maternal intrapartum
78 antibiotic prophylaxis; however, NM incidence caused by *E. coli* remains the same [7, 9].
79 Moreover, NMEC is the main cause of relapsed infections in neonates [10].

80

81 NMEC are categorised genetically using multi-locus sequence typing (ST) or by serotyping
82 based on cell-surface O antigen (O), capsule (K) and flagella (H) antigens. Analysis of
83 NMEC diversity in France revealed ~25% of strains belong to the ST95 clonal complex
84 (STc95) [11], however, a global picture of NMEC epidemiology is lacking. NMEC possess a
85 limited diversity of serotypes, dominated by O18:K1:H7, O1:K1, O7:K1, O16:K1, O83:K1
86 and O45:K1:H7, which together account for >70% of NMEC [12-14]. Notably, ~80% of
87 NMEC express the K1 capsule, a polysaccharide comprising linear homopolymers of α 2-8-
88 linked N-acetyl neuraminic acid [12, 15]. Apart from the K1 capsule, specific NMEC
89 virulence factors are less-well defined, though studies have demonstrated a role for S
90 fimbriae [16], the outer membrane protein OmpA [17], the endothelial invasin IbeA [18] and
91 the cytotoxin necrotising factor CNF1 [19] in translocation of NMEC across the blood-brain
92 barrier and pathogenesis. A large plasmid encoding colicin V (ColV), colicin Ia bacteriocins

93 and several virulence genes including iron-chelating siderophore systems has also been
94 strongly associated with NMEC virulence [20].

95

96 Despite being the second major NM aetiology, genomic studies on NMEC are lacking, with
97 most reporting single NMEC complete genomes. Here we present the genomic analyses of a
98 collection of 58 NMEC strains isolated from seven different geographic regions over 46 years
99 to understand virulence gene content, antibiotic resistance and genomic diversity. In addition,
100 we provide a complete genome for 18 NMEC strains representing different sequence types,
101 serotypes and virulence gene profiles, thus more than tripling the number of available NMEC
102 genomes that can be used as references in future studies. Three infants in our study suffered
103 relapsed NMEC infection, and we show this was caused by the same strain. We further
104 revealed that patients that suffered relapsed infection had severe gut dysbiosis, and detected
105 the infecting strain in the intestinal microflora, suggesting NMEC colonisation of the gut
106 provides a reservoir that can seed repeat infection.

107

108

109 **Results**

110 **Establishment of an NMEC strain collection from geographically diverse locations**

111 A collection of 52 NMEC strains isolated from the blood or cerebrospinal fluid (CSF) of
112 neonates with meningitis was established with the addition of six completely sequenced
113 NMEC genomes available on the NCBI database. This yielded a final set of 58 NMEC strains
114 spanning 1974 to 2020 (Supplementary Table 1). The strains were isolated from seven
115 different geographic locations; Finland (n=17, 29.3%), Sweden (n=14, 24.1%), Australia
116 (n=15, 25.9%), Cambodia (n=7, 12.1%), USA (n=3, 5.2%), France (n=1, 1.7%) and the
117 Netherlands (n=1, 1.7%).

118

119 **ST95 and ST1193 are the two major STs of NMEC**

120 Phylogenetic analysis was performed on the 58 NMEC strains, with an additional eight well-
121 characterised *E. coli* strains included for referencing (EC958, UTI89, MS7163, CFT073,
122 UMN026, 536, APEC01, MG1655) (Supplementary Table 1). The NMEC strains were
123 diverse, and spanned phylogroups A, B2, C, D and F; the majority of strains were from
124 phylogroup B2 (n=48, 82.8%). Overall, the strains belonged to 22 STs, of which 15 STs only
125 contained one strain. ST95 (n=20, 34.5%) and ST1193 (n=9, 15.5%) were the two most
126 common NMEC STs (Figure 1, Supplementary Table 1). ST95 strains were isolated over the
127 entire study period, while ST1193 strains were more recent and only isolated from 2013.
128 Four strains belonged to ST390 (6.9%), which is part of the STc95. One strain belonged to a
129 novel ST designated ST11637, which is part of the ST14 clonal complex (STc14) that also
130 contains ST1193 (Figure 1, Supplementary Table 1). Strains from other common phylogroup
131 B2 extra-intestinal pathogenic *E. coli* (ExPEC) lineages, ST131, ST73 and ST69, as well as
132 several STs associated with environmental sources such as ST48 and ST23, were detected in
133 the collection. However, it is notable that the high incidence of NM associated with ST95 and
134 ST1193 does not reflect the broader high prevalence of major ExPEC clones associated with
135 human infections in the publicly available Enterobase database [21] (Supplementary Figure
136 1), suggesting ST95 and ST1193 exhibit specific virulence features associated with their
137 capacity to cause NM.

138

139 Eighteen NMEC strains were completely sequenced using complementary long-read Oxford
140 Nanopore Technology, enabling accurate comparison of NMEC genome size, genomic island
141 composition and location, and plasmid and prophage diversity (Supplementary Table 2).
142 These strains spanned the diversity in the collection, representing 11 different STs, including

143 two ST1193 strains (one with the dominant O75:H5 serotype and one with an unusual O6:H5
144 serotype), five ST95 strains with different serotypes, and a strain from the novel ST11637.

145

146 **Antibiotic resistance in NMEC**

147 Antibiotic resistance profiling revealed an overall low level of resistance in the collection.

148 The ST1193 strains contained fluoroquinolone resistance defining mutations in *gyrA* (S83L

149 D87N) and *parC* (S80I), as previously described for this lineage [22]. In addition, 77.8% of

150 ST1193 strains (7/9 strains) also harboured at least one gene conferring resistance to

151 aminoglycosides (*aac(3)-IId*, *aadA5*, *aph(3'')-Ib* and *aph(6)-Id*), trimethoprim (*dftA17*) and

152 sulphonamides (*sul1* and *sul2*) (Supplementary Figure 2). Six out of the seven strains from

153 Cambodia had more than one antibiotic resistance gene, likely reflecting increased antibiotic

154 resistance rates in this region [23]. Indeed, in addition to *gyrA* and *parC* mutations for

155 fluoroquinolone resistance, CAM-NMEC-6 contains 14 antibiotic resistance genes (including

156 resistance to third-generation cephalosporins and carbapenems) and CAM-NMEC-4 contains

157 11 antibiotic resistance genes (Supplementary Figure 2).

158

159 **Virulence factors in NMEC**

160 The strains exhibited variable distribution of virulence genes previously linked to NMEC

161 pathogenesis. The most prevalent genes were those involved in iron uptake, including the

162 enterobactin (98%), yersiniabactin (98%), aerobactin (62%) and salmochelin (55%)

163 siderophore systems, and the heme receptors *chuA* (93%) and *hma* (62%) (Figure 1). Also

164 common were the *sitABCD* genes encoding an iron/manganese transporter (98%). The

165 presence of fimbrial and afimbrial adhesins was also diverse. The most prevalent adhesins

166 were type 1 fimbriae (100%), *mat (ecp)* fimbriae (98%) and the *fdeC* adhesin (98%). Genes

167 encoding P and S fimbriae were detected in 36% and 22% of NMEC strains, respectively.

168 The most prevalent toxin was the uropathogenic-specific genotoxin *usp* (83%), which was
169 only found in phylogroup B2 strains. Other toxin genes encoding the serine protease
170 autotransporters Vat (65% prevalence) and Sat (29%), hemolysin (12%) and cytotoxic
171 necrotizing factor-1 (7%) were less prevalent. Other virulence genes included the *asfA*
172 arylsulfatase (95%), the *iss* lipoprotein (76%) and the *ibeA* invasin (33%). The CoIV-plasmid
173 was present in 33% of the strains (Figure 1, Supplementary Table 1). Direct comparison of
174 virulence factors between ST95 and ST1193, the two most dominant NMEC STs, revealed
175 that the ST95 strains contained significantly more virulence factors than the ST1193 strains
176 (Supplementary Table 1, Supplementary Figure 3).

177

178 **NMEC comprise a dominant K1 capsule type and a limited pool of O and H serotypes**

179 The capsule type of the NMEC strains was determined by *in silico* typing. K1 was the
180 dominant capsule type in the collection (43/58 strains, 74.1%) (Figure 1). Thirty-four of these
181 strains were available for capsule testing, and we confirmed K1 expression by ELISA in all
182 but two strains (Supplementary Figure 4). Other capsule types included K2, K5 and K14
183 (Supplementary Table 1). A capsule type could not be resolved for 12 strains, of which eight
184 did not possess a Group II or Group III capsule type based on the absence of the conserved
185 *kpsD* gene (Figure 1, Supplementary Table 1).

186

187 *In silico* serotypes were also determined. O18 was the most common O type (n=16, 27.6%),
188 followed by O75 (n=8, 13.9%) and O2 (n=7, 12.1%). The most dominant H types were H7
189 (n=19, 32.8%), H5 (n=13, 22.4%) and H4 (n=9, 15.5%). The most common serotype was
190 O18:H7:K1 (n=14, 24.1%); these strains belonged to the STc95 (nine ST95, four ST390 and
191 one ST416). The second most common serotype was O75:H5:K1 (n=8, 13.8%); six strains
192 from ST1193 possessed this serotype.

193

194 **NMEC can cause recurrent invasive infection despite appropriate antibiotic treatment**

195 During 2019 – 2020, three patients from which NMEC strains were originally isolated
196 suffered relapsed infection (Figure 1; MS21522, MS21524 and MS22733), providing an
197 opportunity to compare the infecting isolates over time using whole genome sequencing. In
198 all cases, the infecting *E. coli* isolates were susceptible to the therapy, which comprised
199 cefotaxime (50mg/kg/dose 8 hourly), switched to ceftriaxone (100mg/kg/day) to facilitate
200 home parenteral antibiotic administration. Bacterial culture was performed from blood, CSF,
201 urine and/or stool during the infection period (Figure 2).

202

203 ***Patient 1***

204 Patient 1 (0-8 weeks of age) was admitted to the emergency department with fever,
205 respiratory distress and sepsis. The child was diagnosed with meningitis based on a
206 cerebrospinal fluid (CSF) pleocytosis (>2000 white blood cells; WBCs) and a positive blood
207 culture for *E. coli* (MS21522). Two weeks after completion of a 3-week course of
208 appropriately dosed therapy with third-generation cephalosporins as described above, the
209 child developed similar symptoms of fever and irritability. Lumbar puncture was performed
210 and the CSF culture was positive for *E. coli* (MS21576). Both the initial blood culture strain
211 and the relapse CSF strain were non-susceptible to ciprofloxacin and gentamycin, and whole
212 genome sequencing revealed they were identical (ST1193 O18:K1:H5; *fimH64*), with no
213 single nucleotide polymorphisms (SNPs) nor indels (Figure 2A). Unlike the typical ST1193
214 O75 serotype [22], this strain contained a unique O18 serotype. The strain possessed
215 mutations in *gyrA* (S83L D87N) and *parC* (S80I), which explain its resistance to
216 ciprofloxacin, as well as a multidrug resistance IncF plasmid containing genes conferring
217 resistance to aminoglycosides (*aac(3)-IIId*, *aadA5*, *aph(3'')-Ib* and *aph(6)-Id*), trimethoprim

218 (*dfrA17*), sulphonamides (*sul1* and *sul2*) and macrolides (*mphA*) (Supplementary Figure 2).

219 Treatment of the relapse was extended to six weeks of intravenous therapy. At follow-up, no

220 anatomical or immunological abnormality was identified and development is normal.

221

222 ***Patient 2***

223 Patient 2 (0-8 weeks of age) presented to the emergency department with a febrile illness.

224 Blood and urine cultures on admission were positive for *E. coli*. CSF taken 24 hours after

225 treatment revealed pleocytosis (>300 WBCs, >95% polymorphs) but was sterile. The patient

226 completed a 3-week course of appropriately dosed antibiotic therapy with third-generation

227 cephalosporins. In the 6-week period after discharge, the child had several short admissions

228 to hospital, but no infection was identified. At 11 weeks post initial infection, the child was

229 re-admitted to hospital with high fever. CSF cultures were negative and microscopy was

230 normal, but cultures from blood, urine and faeces were all positive for *E. coli*. Whole genome

231 sequencing revealed that all strains belonged to ST537 O75:H5 (*fimH5*; STc14). Pairwise

232 comparison of the relapsed isolates showed that the urine and fecal isolates were identical to

233 the original isolate, while the blood isolate contained one nonsynonymous SNP in the *mdoH*

234 gene encoding a glucan biosynthesis glucosyltransferase (T1358G; V453G). This mutation is

235 located in the large cytoplasmic domain of MdoH likely involved in polymerisation of

236 glucose from UDP glucose; the strain exhibited a mucoid colony morphology suggestive of

237 increased colanic acid production. The strains did not possess plasmids nor antibiotic

238 resistance genes. The infant experienced recurrent urinary tract infections with *E. coli* and

239 other urinary pathogens through infancy despite normal urinary tract anatomy. At follow-up,

240 no other history of invasive infection or identified immunodeficiency were noted, and the

241 child was reported to be developing normally.

242

243 **Patient 3**

244 Patient 3 (0-8 weeks of age) was admitted to the paediatric intensive care unit with fever and
245 seizures. CSF and blood cultured a fully susceptible *E. coli*. Two weeks after completing a
246 four-week course of appropriate therapy with third-generation cephalosporins, the infant was
247 readmitted to hospital with fever and irritability, with further investigation identifying *E. coli*
248 in CSF, urine and blood. Three weeks after the completion of the six-week treatment course,
249 the infant experienced a second relapse, with *E. coli* isolated from both CSF and blood.
250 Whole genome sequencing revealed that all strains were identical and belonged to ST131
251 O25b:K1:H4 (*fimH22*). These strains contained a ColV-virulence plasmid, but did not
252 harbour acquired antibiotic resistance genes. The infant received a further 6-week course of
253 therapy. Imaging studies and immunological work-up were normal. The child exhibited
254 speech delay but no other developmental abnormality was reported at follow-up.

255

256 **The gut as a reservoir to seed relapsed infection**

257 In all three relapsed patients, the causative isolates were susceptible to third-generation
258 cephalosporins, suggesting the existence of a persistent reservoir that could evade the cidal
259 effect of antibiotic treatment and seed repeat infection. Indeed, the fact that the causative *E.*
260 *coli* strain was detected from a fecal sample at the time of the relapsed infection in patient 2
261 (day 77 after initial admission), suggests that NMEC could persist in the gut and cause
262 relapsed infection, an observation that has also been reported for uropathogenic *E. coli* that
263 cause recurrent urinary tract infection [24] and acute pyelonephritis in infants [25].
264 Therefore, we retrospectively examined available stored fecal samples from patient 2 at 8-
265 and 12-week follow-up visits post relapsed infection (days 149 and 174 after initial
266 admission) and patient 3 during treatment and at discharge after the third episode (days 126
267 and 147 after initial admission) using short-read metagenomic sequencing (Figure 3).

268 Although no fecal samples were available for comparative analysis from either patient prior
269 to antibiotic treatment, we observed a low level of diversity in the composition of the
270 microbiome of both patients, consistent with severe dysbiosis. The microbiome of patient 2
271 was dominated by *Enterobacter* (37.4% relative abundance), *Achromobacter* (23.4% relative
272 abundance) and *Bacteroides* (22.7% relative abundance) genera at 8-weeks post relapse
273 infection (day 149 after initial admission), and by *Bacteroides* genera (75.8% relative
274 abundance) at 12-weeks post relapse infection (day 174 after initial admission). The relative
275 abundance of *E. coli* was 2.05% and 4.1% in each of these samples, respectively, and further
276 analysis using StrainGE [26] showed that the strains were most closely matched to the
277 original causative strain MS21524. We further employed complementary long-read
278 metagenomic sequencing to analyse the 8-week post relapse infection sample, which enabled
279 construction of a complete *E. coli* genome that was identical to the causative ST537 (*fimH5*)
280 strain (Figure 2, Figure 3; Supplementary Table 3). In the 12-week post relapse infection
281 fecal sample from patient 2, amplicon sequencing targeting *fimH* identified the presence of *E.*
282 *coli* with the same *fimH* type as the causative strain (*fimH5*). Thus, two independent analyses
283 of samples taken 4 weeks apart demonstrated the existence of the *E. coli* ST537 strain in the
284 intestinal microflora of patient 2. In patient 3, the microbiome was dominated by
285 *Enterococcus* genera at both time points examined (93% and 97.4% relative abundance). We
286 were unable to detect *E. coli* by *fimH* amplicon sequencing and the relative abundance of *E.*
287 *coli* in these fecal samples was extremely low (<0.01%) based on metagenomic sequencing
288 (Supplementary Table 3). The extensive dysbiosis revealed in this patient is likely an
289 outcome of the three rounds of antibiotic treatment.
290

291 **Discussion**

292 In this study, we present a genomic analysis of 58 NMEC strains isolated over 46 years
293 spanning seven different geographic locations and reveal a dominance of ST95 and ST1193
294 strains. We also provide direct evidence to implicate the gut as a reservoir for relapsed
295 infection in some patients despite appropriate antibiotic treatment.

296

297 The majority of the NMEC strains in our study belonged to phylogroup B2 (82.8%), an
298 observation consistent with other reports [27, 28]. These strains were predominantly from
299 two major STs, ST95 and ST1193. Strains from ST95 form a major clonal lineage
300 responsible for urinary tract and bloodstream infections [29, 30], and were identified
301 throughout the period of investigation. This lineage was also previously shown to cause
302 ~25% of NM cases in France in the period 2004-2015 [11], demonstrating its enhanced
303 capacity to cause disseminated infection in newborns. ST1193, on the other hand, was first
304 identified in 2012 [31], and is the second most common fluoroquinolone-resistant *E. coli*
305 lineage after ST131 [22, 32]. ST1193 causing NM was first reported in the USA in 2016 [33].
306 Here, ST1193 accounted for 15.5% of NMEC strains, all of which were isolated from 2013,
307 and was the dominant lineage since this time. This is consistent with a report in China that
308 showed ST1193 was the most common NMEC (21.4%), followed by ST95 (17.9%), between
309 2009-2015 [34]. Concerningly, the ST1193 strains examined here carry genes encoding
310 several aminoglycoside-modifying enzymes, generating a resistance profile that may lead to
311 the clinical failure of empiric regimens such as ampicillin and gentamicin, a therapeutic
312 combination used in many settings to treat NM and early-onset sepsis [35, 36]. This, in
313 combination with reports of co-resistance to third-generation cephalosporins for some
314 ST1193 strains [22, 34], would limit the choice of antibiotic treatments. The dominance of
315 both ST95 and ST1193 in our collection is notable since other widespread *E. coli* phylogroup

316 B2 lineages such as ST131, ST73, ST69 and ST12 do not cause similar rates of NM disease.
317 We speculate this is due to the prevailing K1 polysialic acid capsule serotype found in ST95
318 and the newly emerged ST1193 clone [22, 37] in combination with other virulence factors
319 (Figure 4) and the immature immune system of preterm infants. Understanding the risk of
320 these clones, as well as perinatal transmission and antibiotic resistance patterns, may inform
321 the appropriateness of interventions such as maternal screening or antimicrobial prophylaxis.

322

323 Although reported rarely, *E. coli* recrudescence in NM patients has been documented in
324 several single study reports [38, 39]. In these reports, infants received appropriate antibiotic
325 treatment based on antibiogram profiling and no clear clinical risk factors to explain
326 recrudescence were identified, highlighting our limited understanding of NM aetiology. Here,
327 we tracked NMEC recurrence using whole genome sequencing in three patients that suffered
328 relapsed infection and demonstrated that the strain causing recrudescence was the same as the
329 original causative strain and susceptible to the initial antibiotic therapy. In one patient
330 (patient 2), we identified the causative strain in the stool at days 77, 149 and 174 after initial
331 detection in the bloodstream, providing direct evidence of persistence in the gut, and
332 implicating this site as a reservoir to seed recurrent infection. This strain belonged to ST537
333 (serotype O75:H5) and belongs to the same clonal complex as ST1193 (i.e. STc14).

334

335 This study had several limitations. First, our NMEC strain collection was restricted to seven
336 geographic regions, a reflection of the difficulty in acquiring strains causing this disease.
337 Second, we did not have access to a complete set of stool samples spanning pre- and post-
338 treatment in the relapse patients. This impacted our capacity to monitor *E. coli* persistence
339 and evaluate the effect of antibiotic treatment on changes in the microbiome over time. Third,
340 we did not have access to urine or stool samples from the mother of the infants that suffered

341 recrudescence, and thus cannot rule out mother-to-child transmission as a mechanism of
342 reinfection. Regardless, our study describes the genomic diversity of NMEC, highlighting
343 ST95 and ST1193 as the most important clonal lineages associated with this devastating
344 disease. Although antibiotics are the standard of care for NMEC treatment, we show that
345 even when appropriate antibiotics are used, in some cases they do not eliminate the causative
346 NMEC that resides intestinally. Together with associated antibiotic-driven dysbiosis, this
347 reveals a need to consider diagnostic and therapeutic interventions to mitigate the risk of
348 recrudescence infection.

349

350

351 **Methods**

352 **Ethics statement**

353 The study received ethical approval from the Children's Health Queensland Human Research
354 Ethics Committee (LNR/18/QCHQ/45045). Precise patient details have been removed for
355 ethics compliance; additional de-identified details are available from the corresponding
356 author upon request.

357

358 **Bacterial strains**

359 A collection of 52 NMEC strains isolated from 1974 to 2020 was achieved from Sweden,
360 Finland, Cambodia and Australia. Strains were stored in glycerol at -80°C until use. All
361 strains were cultured in Lysogeny broth. This collection was complemented by the addition
362 of six completely sequenced NMEC genomes available on the NCBI database, namely strains
363 IHE3034, RS218, S88, NMEC58, MCJCHV-1 and CE10.

364

365 **DNA extraction, genome sequencing and analyses**

366 Genome sequencing was performed using paired-end Illumina methodology. Illumina
367 sequencing data were processed by removing adapters and low-quality reads using
368 Trimmomatic v0.36 [40], with a minimum quality score of 10 and minimum read length of
369 50. Trimmed reads were *de novo* assembled using SPAdes v3.12.0 [41] with default
370 parameters. Draft assemblies of the 52 NMEC strains from this study, together with six
371 complete NMEC genomes and eight complete genomes from other characterised *E. coli*
372 representing different phylogroups, were subjected to phylogenetic analysis using parsnp
373 v1.5.3 [42]. A subset of 18 strains were additionally sequenced using Oxford Nanopore
374 Technology long-read sequencing (Nanopore). Complete NMEC genomes were achieved
375 using a combination of Illumina short-read and Nanopore long-read data and analysis
376 employing the MicroPIPE tool [43].

377

378 ***In silico* and molecular analyses**

379 Virulence-associated genes, antibiotic resistance genes, plasmids and serotyping were
380 evaluated using ABRicate (<https://github.com/tseemann/abricate>) with built-in databases [44-
381 47], with the percentage nucleotide identity and coverage cut-off set at 90% and 80%,
382 respectively. Capsule typing was performed employing Kaptive [48] using an in-house *E.*
383 *coli* capsule database [37] and manually checked. Chromosomal point mutations associated
384 with antibiotic resistance were detected using PointFinder [49]. FimH amplicon sequencing
385 was performed as previously described [50, 51]; allelic variants were identified using
386 FimTyper [52].

387

388 **K1 ELISA**

389 K1 capsule expression was detected by ELISA using an anti-polysialic acid antibody single
390 chain Fv fragment [53] as the primary antibody, anti-His antibody and alkaline phosphatase

391 anti-mouse IgG as the secondary and tertiary antibodies, respectively; p-
392 nitrophenylphosphate (Sigma) was used as the substrate. Optical density was measured at 420
393 nm.

394

395 **Metagenomic sequencing and analyses**

396 Metagenomic sequencing was performed on DNA extracted from fecal samples using the
397 Illumina NovaSeq6000 platform. Adapters and low-quality reads were trimmed using
398 Trimmomatic v0.36 [40], employing a minimum quality score of 10 and minimum read
399 length of 50. Sequencing reads corresponding to human DNA were discarded by mapping the
400 trimmed reads to the human genome hg38 (accession number GCA_000001405.29) using
401 bowtie2 [54]. Taxonomical profiling was performed with Kraken2 [55] followed by Bracken
402 [56].

403

404 **Long-read metagenomic sequencing**

405 Long-read metagenomic sequencing was performed on DNA extracted from a fecal sample.
406 A HiFi gDNA library was prepared using the SMRTbell Express Template Prep Kit 2.0
407 (PacBio, 100-938-900) according to the low input protocol (PacBio, PN 101-730-400
408 Version 06 [June 2020]). As the sample DNA was already fragmented with a tight peak
409 (mode size 9.4 kb), no shearing was performed; the sample was concentrated using Ampure
410 PB beads (PacBio, PCB-100-265-900) and used directly as input into library preparation.
411 The entire quantity of purified DNA (360ng) was used to make the library as follows. The
412 DNA was treated to remove single-stranded overhangs, followed by a DNA damage repair
413 reaction and an end-repair/A-tailing reaction. Overhang barcoded adapters were ligated to the
414 A-tailed library fragments, followed by a nuclease treatment to remove damaged library
415 fragments, and then purification with AMPure PB beads. The library was size-selected to

416 remove fragments <3kb using AMPure PB beads. The final purified, size-selected library was
417 quantified on the Qubit fluorometer using the Qubit dsDNA HS assay kit (Invitrogen,
418 Q32854) to assess concentration, and run on the Agilent Femto Pulse using the 55 kb BAC
419 Analysis Kit (Agilent, FP-1003-0275) to assess fragment size distribution.

420

421 Sequencing was performed using the PacBio Sequel II (software/chemistry v10.1). The
422 library pool was prepared for sequencing according to the SMRT Link (v10.1) sample setup
423 calculator, following the standard protocol for Diffusion loading with Ampure PB bead
424 purification, using Sequencing Primer v5, Sequel II Binding Kit v2.2 and the Sequel II DNA
425 Internal Control v1. Adaptive loading was utilised, with nominated on-plate loading
426 concentration of 80pM. The polymerase-bound library was sequenced on 1 SMRT Cell with
427 a 30-hour movie time plus a 2-hour pre-extension using the Sequel II Sequencing 2.0 Kit
428 (PacBio, 101-820-200) and SMRT Cell 8M (PacBio, 101-389-001).

429

430 After sequencing, the data was processed to generate CCS reads and demultiplex samples
431 using the default settings of the CCS with Demultiplexing application in SMRT Link (v10.1).
432 The demultiplexed reads were assembled *de novo* using Hifiasm [57]. Assembled contigs
433 were subject to taxonomic profiling using kraken2 [55] and fastANI [58]. Contigs
434 taxonomically assigned as *Escherichia coli* were subjected to *in silico* sequence typing using
435 MLST (<https://github.com/tseemann/mlst>) and mlst profiles from PubMLST [59].

436

437 **Author Contributions:** Conceptualization, MAS, AB, BW-W and ADI.; Investigation,
438 NTKN, M-DP, SJH, KMP, LA-F, BMF, SBA, and TM.; Formal analysis, NTKN, M-DP,
439 ADI and MAS., Resources, PNAH, SAB, SS, HB, PT, AB, BW-W, ADI and MAS.; Writing
440 – Original Draft, NTKN, ADI and MAS.; Writing – Review & Editing, All Authors.;

441 Supervision, ADI and MAS.; Funding Acquisition, NTKN, M-DP, PNAH, SAB, SS, PT,
442 ADI, MAS.

443

444 **Declaration of interests:** The authors declare that they have no conflict of interest.

445

446 **Data sharing:** Genome sequence data have been deposited in the Sequence Read Archive

447 under the BioProjects PRJNA757133 and PRJNA893826. Sample accession numbers are

448 listed in Supplementary Table 4.

449

450 **Acknowledgments**

451 The authors would like to thank Michelle Bauer for technical expertise and the laboratories

452 contributing the isolates, Pathology Queensland and Mater Pathology. At the time of the

453 study SS was affiliated with Mater Pathology, South Brisbane, Australia. This work was

454 supported by project grants APP1181958 and APP2001431 (to MAS, MDP and NTKN) and

455 an Investigator grant GNT1197743 (to ADI) from the National Health and Medical Research

456 Council of Australia (NHMRC), a Children's Hospital Foundation Innovator grant (50270, to

457 MAS, ADI, PNAH, SAB and SS), an Australian Infectious Diseases Research Centre grant

458 (to MAS, ADI and NTKN), a grant from the Genome Innovation Hub at the University of

459 Queensland, and a grant from the Wellcome Trust to PT (Grant number 220211). For the

460 purpose of open access, the author (PT) has applied a CC BY public copyright licence to any

461 Author Accepted Manuscript version arising from this submission.

462

463

464 References


- 465 1. Doctor BA, Newman N, Minich NM, Taylor HG, Fanaroff AA, Hack M. Clinical
466 outcomes of neonatal meningitis in very-low birth-weight infants. *Clin Pediatr (Phila)*
467 **2001**; 40(9): 473-80.
- 468 2. Stevens JP, Eames M, Kent A, Halket S, Holt D, Harvey D. Long term outcome of
469 neonatal meningitis. *Arch Dis Child Fetal Neonatal Ed* **2003**; 88(3): F179-84.
- 470 3. Harvey D, Holt DE, Bedford H. Bacterial meningitis in the newborn: a prospective
471 study of mortality and morbidity. *Semin Perinatol* **1999**; 23(3): 218-25.
- 472 4. Ouchenir L, Renaud C, Khan S, et al. The Epidemiology, Management, and Outcomes
473 of Bacterial Meningitis in Infants. *Pediatrics* **2017**; 140(1).
- 474 5. Gaschignard J, Levy C, Romain O, et al. Neonatal Bacterial Meningitis: 444 Cases in 7
475 Years. *Pediatr Infect Dis J* **2011**; 30(3): 212-7.
- 476 6. Basmaci R, Bonacorsi S, Bidet P, et al. Escherichia Coli Meningitis Features in 325
477 Children From 2001 to 2013 in France. *Clin Infect Dis* **2015**; 61(5): 779-86.
- 478 7. May M, Daley AJ, Donath S, Isaacs D, Australasian Study Group for Neonatal I. Early
479 onset neonatal meningitis in Australia and New Zealand, 1992-2002. *Arch Dis Child*
480 *Fetal Neonatal Ed* **2005**; 90(4): F324-7.
- 481 8. Holt DE, Halket S, de Louvois J, Harvey D. Neonatal meningitis in England and Wales:
482 10 years on. *Arch Dis Child Fetal Neonatal Ed* **2001**; 84(2): F85-9.
- 483 9. van der Flier M. Neonatal meningitis: small babies, big problem. *Lancet Child Adolesc*
484 *Health* **2021**; 5(6): 386-7.
- 485 10. Anderson SG, Gilbert GL. Neonatal gram negative meningitis: a 10-year review, with
486 reference to outcome and relapse of infection. *J Paediatr Child Health* **1990**; 26(4):
487 212-6.
- 488 11. Geslain G, Birgy A, Adiba S, et al. Genome sequencing of strains of the most
489 prevalent clonal group of O1:K1:H7 Escherichia coli that causes neonatal meningitis
490 in France. *BMC Microbiol* **2019**; 19(1): 17.
- 491 12. Sarff LD, McCracken GH, Schiffer MS, et al. Epidemiology of Escherichia coli K1 in
492 healthy and diseased newborns. *Lancet* **1975**; 1(7916): 1099-104.
- 493 13. Plainvert C, Bidet P, Peigne C, et al. A new O-antigen gene cluster has a key role in
494 the virulence of the Escherichia coli meningitis clone O45:K1:H7. *J Bacteriol* **2007**;
495 189.
- 496 14. Bidet P, Mahjoub-Messai F, Blanco J, et al. Combined multilocus sequence typing and
497 O serogrouping distinguishes Escherichia coli subtypes associated with infant
498 urosepsis and/or meningitis. *J Infect Dis* **2007**; 196(2): 297-303.
- 499 15. Robbins JB, McCracken GH, Jr., Gotschlich EC, Orskov F, Orskov I, Hanson LA.
500 Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. *N*
501 *Engl J Med* **1974**; 290(22): 1216-20.
- 502 16. Prasadarao NV, Wass CA, Hacker J, Jann K, Kim KS. Adhesion of S-fimbriated
503 Escherichia coli to brain glycolipids mediated by sfaA gene-encoded protein of S-
504 fimbriae. *J Biol Chem* **1993**; 268(14): 10356-63.
- 505 17. Prasadarao NV, Wass CA, Weiser JN, Stins MF, Huang SH, Kim KS. Outer membrane
506 protein A of Escherichia coli contributes to invasion of brain microvascular
507 endothelial cells. *Infect Immun* **1996**; 64(1): 146-53.
- 508 18. Huang SH, Chen YH, Kong G, et al. A novel genetic island of meningitic Escherichia
509 coli K1 containing the ibeA invasion gene (GimA): functional annotation and carbon-

- 510 source-regulated invasion of human brain microvascular endothelial cells. *Funct*
511 *Integr Genomics* **2001**; 1(5): 312-22.
- 512 19. Wang MH, Kim KS. Cytotoxic necrotizing factor 1 contributes to *Escherichia coli*
513 meningitis. *Toxins (Basel)* **2013**; 5(11): 2270-80.
- 514 20. Peigne C, Bidet P, Mahjoub-Messai F, et al. The plasmid of *Escherichia coli* strain S88
515 (O45:K1:H7) that causes neonatal meningitis is closely related to avian pathogenic *E.*
516 *coli* plasmids and is associated with high-level bacteremia in a neonatal rat
517 meningitis model. *Infect Immun* **2009**; 77(6): 2272-84.
- 518 21. Zhou Z, Alikhan NF, Mohamed K, Fan Y, Agama Study G, Achtman M. The Enterobase
519 user's guide, with case studies on *Salmonella* transmissions, *Yersinia pestis*
520 phylogeny, and *Escherichia coli* core genomic diversity. *Genome Res* **2020**; 30(1): 138-52.
- 521 22. Johnson TJ, Elnekave E, Miller EA, et al. Phylogenomic Analysis of Extraintestinal
522 Pathogenic *Escherichia coli* Sequence Type 1193, an Emerging Multidrug-Resistant
523 Clonal Group. *Antimicrob Agents Chemother* **2019**; 63(1).
- 524 23. Reed TAN, Krang S, Miliya T, et al. Antimicrobial resistance in Cambodia: a review. *Int*
525 *J Infect Dis* **2019**; 85: 98-107.
- 526 24. Forde BM, Roberts LW, Phan MD, et al. Population dynamics of an *Escherichia coli*
527 ST131 lineage during recurrent urinary tract infection. *Nat Commun* **2019**; 10(1):
528 3643.
- 529 25. Tullus K, Horlin K, Svenson SB, Kallenius G. Epidemic outbreaks of acute
530 pyelonephritis caused by nosocomial spread of P fimbriated *Escherichia coli* in
531 children. *J Infect Dis* **1984**; 150(5): 728-36.
- 532 26. van Dijk LR, Walker BJ, Straub TJ, et al. StrainGE: a toolkit to track and characterize
533 low-abundance strains in complex microbial communities. *Genome Biol* **2022**; 23(1):
534 74.
- 535 27. Wijetunge DS, Gongati S, DebRoy C, et al. Characterizing the pathotype of neonatal
536 meningitis causing *Escherichia coli* (NMEC). *BMC Microbiol* **2015**; 15: 211.
- 537 28. Bidet P, Mahjoub-Messai F, Blanco J, et al. Combined Multilocus Sequence Typing
538 and O Serogrouping Distinguishes *Escherichia coli* Subtypes Associated with Infant
539 Urosepsis and/or Meningitis. *J Infect Dis* **2007**; 196.
- 540 29. Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, Pitout JDD. Global Extraintestinal
541 Pathogenic *Escherichia coli* (ExPEC) Lineages. *Clin Microbiol Rev* **2019**; 32(3).
- 542 30. Kallonen T, Brodrick HJ, Harris SR, et al. Systematic longitudinal survey of invasive
543 *Escherichia coli* in England demonstrates a stable population structure only
544 transiently disturbed by the emergence of ST131. *Genome Res* **2017**.
- 545 31. Platell JL, Trott DJ, Johnson JR, et al. Prominence of an O75 clonal group (clonal
546 complex 14) among non-ST131 fluoroquinolone-resistant *Escherichia coli* causing
547 extraintestinal infections in humans and dogs in Australia. *Antimicrob Agents*
548 *Chemother* **2012**; 56(7): 3898-904.
- 549 32. Tchesnokova VL, Rechkina E, Larson L, et al. Rapid and Extensive Expansion in the
550 United States of a New Multidrug-resistant *Escherichia coli* Clonal Group, Sequence
551 Type 1193. *Clin Infect Dis* **2019**; 68(2): 334-7.
- 552 33. Nielsen DW, Ricker N, Barbieri NL, et al. Complete Genome Sequence of the
553 Multidrug-Resistant Neonatal Meningitis *Escherichia coli* Serotype O75:H5:K1 Strain
554 mcjchv-1 (NMEC-O75). *Microbiol Resour Announc* **2018**; 7(10).
- 555 34. Ding Y, Zhang J, Yao K, Gao W, Wang Y. Molecular characteristics of the new
556 emerging global clone ST1193 among clinical isolates of *Escherichia coli* from


- 557 neonatal invasive infections in China. *Eur J Clin Microbiol Infect Dis* **2021**; 40(4): 833-
558 40.
- 559 35. Fleiss N, Schwabenbauer K, Randis TM, Polin RA. What's new in the management of
560 neonatal early-onset sepsis? *Arch Dis Child Fetal Neonatal Ed* **2023**; 108(1): 10-4.
- 561 36. Fuchs A, Bielicki J, Mathur S, Sharland M, Van Den Anker JN. Reviewing the WHO
562 guidelines for antibiotic use for sepsis in neonates and children. *Paediatr Int Child*
563 *Health* **2018**; 38(sup1): S3-S15.
- 564 37. Goh KGK, Phan MD, Forde BM, et al. Genome-Wide Discovery of Genes Required for
565 Capsule Production by Uropathogenic *Escherichia coli*. *mBio* **2017**; 8(5).
- 566 38. Vissing NH, Monster MB, Nordly S, et al. Relapse of Neonatal *Escherichia coli*
567 Meningitis: Did We Miss Something at First? *Children (Basel)* **2021**; 8(2).
- 568 39. Bingen E, Cave H, Aujard Y, et al. Molecular analysis of multiply recurrent meningitis
569 due to *Escherichia coli* K1 in an infant. *Clin Infect Dis* **1993**; 16(1): 82-5.
- 570 40. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
571 sequence data. *Bioinformatics* **2014**; 30(15): 2114-20.
- 572 41. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm
573 and its applications to single-cell sequencing. *J Comput Biol* **2012**; 19(5): 455-77.
- 574 42. Treangen TJ, Ondov BD, Koren S, Phillippy AM. The Harvest suite for rapid core-
575 genome alignment and visualization of thousands of intraspecific microbial genomes.
576 *Genome Biol* **2014**; 15(11): 524.
- 577 43. Murigneux V, Roberts LW, Forde BM, et al. MicroPIPE: validating an end-to-end
578 workflow for high-quality complete bacterial genome construction. *BMC Genomics*
579 **2021**; 22(1): 474.
- 580 44. Chen L, Zheng D, Liu B, Yang J, Jin Q. VFDB 2016: hierarchical and refined dataset for
581 big data analysis--10 years on. *Nucleic Acids Res* **2016**; 44(D1): D694-7.
- 582 45. Feldgarden M, Brover V, Haft DH, et al. Using the NCBI AMRFinder Tool to Determine
583 Antimicrobial Resistance Genotype-Phenotype Correlations Within a Collection of
584 NARMS Isolates. **2019**: 550707.
- 585 46. Carattoli A, Zankari E, Garcia-Fernandez A, et al. In silico detection and typing of
586 plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob*
587 *Agents Chemother* **2014**; 58(7): 3895-903.
- 588 47. Ingle DJ, Valcanis M, Kuzevski A, et al. In silico serotyping of *E. coli* from short read
589 data identifies limited novel O-loci but extensive diversity of O:H serotype
590 combinations within and between pathogenic lineages. *Microb Genom* **2016**; 2(7):
591 e000064.
- 592 48. Wyres KL, Wick RR, Gorrie C, et al. Identification of *Klebsiella* capsule synthesis loci
593 from whole genome data. *Microb Genom* **2016**; 2(12): e000102.
- 594 49. Zankari E, Allesoe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: a
595 novel web tool for WGS-based detection of antimicrobial resistance associated with
596 chromosomal point mutations in bacterial pathogens. *J Antimicrob Chemother* **2017**;
597 72(10): 2764-8.
- 598 50. Willner D, Low S, Steen JA, et al. Single clinical isolates from acute uncomplicated
599 urinary tract infections are representative of dominant in situ populations. *mBio*
600 **2014**; 5(2): e01064-13.
- 601 51. Chen Z, Phan MD, Bates LJ, et al. The urinary microbiome in patients with refractory
602 urge incontinence and recurrent urinary tract infection. *Int Urogynecol J* **2018**;
603 29(12): 1775-82.

- 604 52. Roer L, Tchesnokova V, Allesoe R, et al. Development of a Web Tool for Escherichia
605 coli Subtyping Based on fimH Alleles. *J Clin Microbiol* **2017**; 55(8): 2538-43.
- 606 53. Nagae M, Ikeda A, Hane M, et al. Crystal structure of anti-polysialic acid antibody
607 single chain Fv fragment complexed with octasialic acid: insight into the binding
608 preference for polysialic acid. *J Biol Chem* **2013**; 288(47): 33784-96.
- 609 54. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
610 **2012**; 9(4): 357-9.
- 611 55. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2.
612 *Genome Biol* **2019**; 20(1): 257.
- 613 56. Jennifer Lu FPB, Peter Thielen, Steven L. Salzberg. Bracken: estimating species
614 abundance in metagenomics data. *PeerJ Computer Science* **2017**; 3(e104).
- 615 57. Cheng H, Concepcion GT, Feng X, Zhang H, Li H. Haplotype-resolved de novo
616 assembly using phased assembly graphs with hifiasm. *Nat Methods* **2021**; 18(2): 170-
617 5.
- 618 58. Jain C, Rodriguez RL, Phillippy AM, Konstantinidis KT, Aluru S. High throughput ANI
619 analysis of 90K prokaryotic genomes reveals clear species boundaries. *Nat Commun*
620 **2018**; 9(1): 5114.
- 621 59. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the
622 population level. *BMC Bioinformatics* **2010**; 11: 595.
- 623
- 624

625 **Figures**



626
 627 **Figure 1.** Maximum likelihood phylogram displaying the relationship of the NMEC strains with their
 628 associated serotype and virulence factor profile. Non-NMEC strains used in the analysis for
 629 referencing are italicized. The phylogram was built and recombination regions removed employing
 630 Parsnp, using 185,911 core single nucleotide polymorphisms (SNPs) and NMEC strain IHE3034 as
 631 the reference. The scale bar indicates branch lengths in numbers of SNPs. NMEC strains with
 632 available complete genomes are bold-italicized, while NMEC strains that were completely sequenced
 633 in this study are indicated in bold and marked with an asterisk. The NMEC strains that caused
 634 relapsed infection in this study are indicated in red. Branches are colored according to phylogroups:
 635 orange, phylogroup F; red, phylogroup C; green, phylogroup A; violet, phylogroup D and blue,
 636 phylogroup B2.



637


638

Figure 2. Infection and treatment profile of patients suffering relapsed infection. Indicated is the hospital admission history of patients, together with the timeline of sample collection, identified *E. coli* isolates and their infection source, and strain identification based on whole genome sequencing, metagenomic sequencing (MetaWGS) or *fimH* amplicon sequencing. Genomic relatedness is indicated based on the number of single nucleotide polymorphisms (SNPs). The time of admission for the initial episode is indicated as Day 0, with subsequent timepoints indicated as days post initial admission. Admission and discharge days are indicated in red and green, respectively.


645

646

A. Patient 2



B. Patient 3




647

648 **Figure 3.** Relative abundance of bacterial genera ($\geq 0.01\%$) in the gut microbiome of patient 2 at 8-
649 and 12-week follow-up post relapsed infection (days 149 and 174 after initial admission) (A) and
650 patient 3 during treatment and at discharge after the third episode (days 126 and 147 after initial
651 admission) (B).

652

653



654

655 **Figure 4.** Summary of key NMEC virulence genes based on genome profiling performed in this
656 study. Shown are shared virulence genes common to most NMEC, as well as ST95- and ST1193-
657 specific NMEC virulence genes. Figure created with BioRender.com.

Supplementary information




Figure S1. Number of human-derived *E. coli* strains from ST95, ST1193, ST38, ST131, ST73, ST10 and ST69 available in the Enterobase database. Strains were stratified based on their year of isolation, spanning the periods before 2000, 2001-2005, 2006-2010, 2011-2015 and 2016-2022.




Figure S3. ST95 NMEC strains contain more virulence factors than ST1193 NMEC strains. (A) The number of virulence genes (grouped as in Fig.1) for each strain within each ST. (B) The number of virulence genes grouped by their functions in ST95 versus ST1193 strains. P-value were calculated using Mann-Whitney two-tailed unpaired test.




Figure S4. K1 capsule production in NMEC. K1 capsule production was detected by ELISA using a monoclonal antibody specific for polysialic acid. Strains with an $OD_{420} > 0.133$ (mean + 3 standard deviations of a negative control *kpsD* mutant; dashed line) were considered positive for K1 capsule production. Data points represent independent biological replicates with horizontal lines as the mean.